Vascular endothelial growth factor (VEGF) expression increased significantly in the\npathogenesis of age-related macular degeneration, which induced the formation of pathological blood\nvessels. Dexamethasone is an exogenous anti-angiogenic drug while bevacizumab is an endogenous\nanti-angiogenic drug. They both have been widely used in ophthalmology. However, independent\nadministration is not enough to completely block the development of choroidal neovascularization\n(CNV), and the number of eyes vitreous injections is limited. Reasonable combination of drugs may\nproduce significantly better therapeutic effect than single drug treatment. The cyclic RGD (cRGD)\npeptide has a particularly high affinity with retinal pigment epithelial cells, where VEGF secretes from.\nIn this study, we prepared nanoparticles of bevacizumab and dexamethasone with cRGD peptide\nas the target (aBev/cRGD-DPPNs). The particle size of the aBev/cRGD-DPPNs was...................
Loading....